InCarda Therapeutics
Membership Level: Standard Community
InCarda Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for cardiac arrhythmias. The company is backed by leading institutional healthcare investors, Deerfield Management and HealthCap. InCarda’s lead development program is a novel, orally inhaled flecainide formulation intended to treat recent-onset, symptomatic paroxysmal atrial fibrillation rapidly. InCarda is led by former BioUtah Board Chair Myles Greenberg.
More